following a full submission:
apalutamide (Erleada®) is accepted for use within NHS Scotland.
Indication under review: treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Apalutamide plus ADT significantly improved radiographic progression-free survival (rPFS) and overall survival compared with placebo plus ADT in adults with mHSPC.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- apalutamide (Erleada)
- SMC ID:
- SMC2472
- Indication:
In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2022